Referencia 1
1. Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23:215-224
2. Katzmann JA, et al. Screening panels for detection of monoclonal gammopathies.Clin Chem 2009; 55:1517-22
3. Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology 2014; 15:e538-e548
4. Myeloma: diagnosis and management. NICE Guidelines NG35, 2016
5. Holding S, et al. Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies. Clin Chem Lab Med 2011; 49:83-8
6. Dejoie T, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood 2016; 128:2941-2948
7. Kyle RA, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med 2018; 378:241-249
8. Kyle RA, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564-569
9. Kyle RA, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24:1121-1127
10. Katzmann J, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2013; 27:208-212